Sera Prognostics Inc

NASDAQ SERA

Data sourced from

and

Download Data

Sera Prognostics Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2024: USD 206.00 K

Sera Prognostics Inc Revenue is USD 206.00 K for the Trailing 12 Months (TTM) ending March 31, 2024, a -37.58% change year over year. The revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Sera Prognostics Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 330.00 K, a 208.41% change year over year.
Sera Prognostics Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 107.00 K, a 256.67% change year over year.
Sera Prognostics Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 30.00 K, a 275.00% change year over year.
Sera Prognostics Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 8.00 K.

NASDAQ: SERA

Sera Prognostics Inc

CEO	Dr. Gregory C. Critchfield M.D., M.S.
IPO Date	July 15, 2021
Location	United States
Headquarters	2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Employees	55
Sector	Healthcare
Industry	Diagnostics & research

Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key trends